These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 18421052)

  • 21. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 22. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.
    O'Neil BH; Goldberg RM
    Oncologist; 2008 Oct; 13(10):1074-83. PubMed ID: 18922828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
    Goffin J; Baral S; Tu D; Nomikos D; Seymour L
    Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
    Alper K; Schwartz KA; Kolts RL; Khan A
    Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
    Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
    J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
    [No Abstract]   [Full Text] [Related]  

  • 34. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.
    Talarico L; Chen G; Pazdur R
    J Clin Oncol; 2004 Nov; 22(22):4626-31. PubMed ID: 15542812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies.
    Yau T; Chan P; Ching Chan Y; Wong BC; Liang R; Epstein RJ
    Aliment Pharmacol Ther; 2008 Jun; 27(11):997-1005. PubMed ID: 18363897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.
    Kalinsky K; Hershman DL
    J Comp Eff Res; 2013 Jul; 2(4):393-403. PubMed ID: 24236681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
    [No Abstract]   [Full Text] [Related]  

  • 40. New drug approved for colorectal cancer.
    FDA Consum; 2002; 36(5):2. PubMed ID: 12412532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.